Alphatec Holdings, Inc. (NASDAQ:ATEC) Director Karen K. Mcginnis Sells 3,963 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) Director Karen K. Mcginnis sold 3,963 shares of the firm's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $12.11, for a total transaction of $47,991.93. Following the completion of the transaction, the director now directly owns 68,709 shares of the company's stock, valued at approximately $832,065.99. This trade represents a 5.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alphatec Stock Performance

Shares of ATEC stock traded down $0.31 during midday trading on Friday, hitting $11.06. 1,994,477 shares of the company were exchanged, compared to its average volume of 2,060,228. The firm has a market capitalization of $1.62 billion, a P/E ratio of -8.64 and a beta of 1.10. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The firm's 50 day moving average price is $11.68 and its two-hundred day moving average price is $10.82. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $13.14.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business's quarterly revenue was up 22.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) EPS. As a group, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of Alphatec

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Comerica Bank raised its stake in Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after purchasing an additional 1,248 shares in the last quarter. Quarry LP raised its stake in Alphatec by 79.2% in the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock worth $49,000 after purchasing an additional 2,375 shares in the last quarter. Larson Financial Group LLC acquired a new stake in Alphatec in the 1st quarter worth about $54,000. Lazard Asset Management LLC acquired a new stake in Alphatec in the 4th quarter worth about $76,000. Finally, AlphaQuest LLC acquired a new stake in Alphatec in the 4th quarter worth about $80,000. Institutional investors own 66.35% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ATEC shares. Wall Street Zen raised shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler reissued an "overweight" rating and issued a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Finally, HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Alphatec currently has an average rating of "Moderate Buy" and an average target price of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.